All In Biotech

Drug Trial Radar · NCT02219932

Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis

A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis (ENHANCE)

Last checked: Nov 20, 2026Latest source record: Mar 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 646 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

646

Actual

Start

Sep 2014

Primary completion

Feb 2016

Study completion Feb 2016

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Aug 19, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to determine whether prolonged-release fampridine (10 mg twice daily) has a clinically meaningful effect on participant-reported walking ability over a 24-week study period. The secondary objectives are: to determine whether prolonged-release fampridine 10 mg taken twice daily (BID) has a clinically meaningful effect on dynamic and static balance, physical impact of multiple sclerosis (MS), and upper extremity function over a 24-week study period; to evaluate criteria for early assessment of response to fampridine that can predict clinically meaningful benefits in walking ability and balance; to assess the safety and tolerability of prolonged-release fampridine 10 mg twice daily over a 24-week treatment period.

Conditions

  • Multiple Sclerosis

Interventions

  • fampridineDrug

  • PlaceboDrug

    Matched placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Achieving a Mean Improvement of ≥ 8 Points From Baseline on the Multiple Sclerosis Walking Scale (MSWS-12) Over 24 WeeksTime frame: Baseline to 24 weeks

Locations

87 sites in 11 countries. Site status is shown where the registry gives one.

  • Research site

    Cullman, Alabama

  • Research site

    Phoenix, Arizona

  • Research site

    San Diego, California

  • Research site

    Bradenton, Florida

  • Research Site

    Orlando, Florida

  • Research site

    Tampa, Florida

  • Research site

    Tampa, Florida

  • Research site

    West Palm Beach, Florida

  • Research site

    Lexington, Kentucky

  • Research site

    New Bedford, Massachusetts

  • Research site

    Detroit, Michigan

  • Research site

    Chesterfield, Missouri

  • Research site

    Rochester, New York

  • Research site

    Charlotte, North Carolina

  • Research site

    Charlotte, North Carolina

  • Research site

    Columbus, Ohio

  • Research site

    Roanoke, Virginia

  • Research site

    Pleven, Bulgaria

  • Research site

    Plovdiv, Bulgaria

  • Research site

    Sofia, Bulgaria

  • Research site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research site

    Sofia, Bulgaria

  • Research site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research site

    Brno, Czechia

  • Research site

    Brno, Czechia

  • Research site

    Choceň, Czechia

  • Research site

    Havířov, Czechia

  • Research site

    Jihlava, Czechia

  • Research site

    Pardubice, Czechia

  • Research site

    Prague, Czechia

  • Research site

    Prague, Czechia

  • Research site

    Teplice, Czechia

  • Research site

    Helsinki, Finland

  • Research site

    Oulu, Finland

  • Research site

    Tampere, Finland

  • Research site

    Turku, Finland

  • Research Site

    Gallarate, Italy

  • Research site

    Messina, Italy

Showing 40 of 87 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.